PulmPEEPs 89. Idiopathic Pulmonary Fibrosis Treatment: RFJC – INPULSIS
Nov 12, 2024
In this engaging discussion, Robert Wharton, a pulmonary fellow at Johns Hopkins, and Nicole Ng, an Assistant Professor at Mount Sinai specializing in interstitial lung disease, delve into the complexities of treating Idiopathic Pulmonary Fibrosis (IPF). They analyze the landmark INPULSIS trials and the efficacy of Nintedanib, highlighting its impact on lung function. The duo discusses challenges like participant selection in clinical trials, adverse effects of the drug, and the importance of personalized treatment strategies to improve patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Challenges in ILD Treatment
- Before 2014, IPF treatment options were limited, with many therapies proving ineffective or even harmful.
- This lack of effective treatment made lung transplantation the primary management option for IPF.
Targeting Tyrosine Kinases
- Nintedanib targets tyrosine kinases involved in fibrogenic growth factor production.
- The INPULSIS trials included patients diagnosed with IPF within five years and excluded younger patients and those with longer disease duration.
IPF Diagnosis
- Surgical lung biopsy, seeking a UIP pattern, was the gold standard for IPF diagnosis.
- The INPULSIS trials required rigorous diagnostic criteria, including HRCT and biopsy, to ensure accurate patient selection.